VCEL
Vericel Corp
NASDAQ · Biotechnology
$36.19
+0.81 (+2.29%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 232.15M | 201.96M | 161.47M | 156.14M | 179.63M |
| Net Income | 10.14M | 7.94M | 29.76M | 35.53M | 31.27M |
| EPS | — | — | — | — | — |
| Profit Margin | 4.4% | 4.2% | 18.4% | 22.8% | 17.4% |
| Rev Growth | +15.0% | +15.0% | -9.0% | +24.7% | +19.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 2.10M | 2.10M | 710.18M | 622.73M | 660.37M |
| Total Equity | 913.04M | 913.04M | 988.33M | 997.81M | 1.08B |
| D/E Ratio | 0.00 | 0.00 | 0.72 | 0.62 | 0.61 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 10.00M | 8.26M | 51.23M | 44.60M | 53.31M |
| Free Cash Flow | — | — | 38.71M | 32.60M | 24.70M |